These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29500171)

  • 1. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
    Mehta-Shah N; Bartlett NL
    Blood; 2018 Apr; 131(15):1698-1703. PubMed ID: 29500171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
    Othman T; Herrera A; Mei M
    Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Therapies in the Treatment of Hodgkin Lymphoma.
    Andrade-Gonzalez X; Ansell SM
    Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for the treatment of Hodgkin lymphoma.
    Donato EM; Fernández-Zarzoso M; De La Rubia J
    Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
    Epperla N; Hamadani M
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):247-253. PubMed ID: 34889401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatment concepts in Hodgkin lymphoma.
    Glimelius I; Diepstra A
    J Intern Med; 2017 Mar; 281(3):247-260. PubMed ID: 27991731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.
    Wang Y; Nowakowski GS; Wang ML; Ansell SM
    J Hematol Oncol; 2018 Apr; 11(1):57. PubMed ID: 29685160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of pathobiology and therapies for classic Hodgkin lymphoma.
    Khan M; Hagemeister F; Wang M; Ahmed S
    Blood Rev; 2022 Sep; 55():100949. PubMed ID: 35396126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
    Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
    Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
    Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
    Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
    Goyal SD; Bartlett NL
    Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
    Grover NS; Dittus C; Thakkar A; Beaven AW
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):510-518. PubMed ID: 38066906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
    Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
    Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma].
    Michot JM; Lazarovici J
    Rev Prat; 2023 Jun; 73(6):641-650. PubMed ID: 37458554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
    Bartlett NL
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.